Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

Association between vitamin D receptor gene polymorphisms and genetic susceptibility to benign prostatic hyperplasia: A systematic review and meta-analysis

Source: Article title. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Systematic review.

Systematic review

Uses explicit methods to identify, assess and summarise research on a defined question.

Meta-analysis reported · Blinding not applicable to this review · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Association between vitamin D receptor gene polymorphisms and genetic susceptibility to benign prostatic hyperplasia: A systematic review and meta-analysis

Source: Article title.

Association between vitamin D receptor gene polymorphisms and genetic susceptibility to benign prostatic hyperplasia: A systematic review and meta-analysis

Source: Article title.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Full studies

Association between vitamin D receptor gene polymorphisms and genetic susceptibility to benign prostatic hyperplasia: A systematic review and meta-analysis

Systematic review · Medicine · 2024

Original publication title

Association between vitamin D receptor gene polymorphisms and genetic susceptibility to benign prostatic hyperplasia: A systematic review and meta-analysis

Li Ruan

Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

In conclusion, this meta-analysis might be the most updated one to assess the association between VDR polymorphisms and the BPH risk. With the limited number of included publications, our analysis evaluated the association of VDR polymorphisms with the risk of BPH, but not the progression of BPH. Thus, larger sample size studies should be carried out.

An extract from the source publication. Read it in context.

At a glance

Study background

What background does the paper provide?

Benign prostatic hyperplasia (BPH), a common benign neoplastic disease in aging male, has highly complex mechanisms and has become a significant worldwide public health issue.[1] Although many studies have been conducted in the past decades, the etiology of BPH cannot be completely explained. Moreover, as the population grows and ages, BPH brings with it a greater burden of health care and financial expense.[2] Lower urinary tract symptoms due to clinical BPH include nocturia, urgency, and frequency, which can obstruct bladder outlet, resulting in declining quality of life.[3,4] Some experiments suggested that the risk of BPH might be associated with many factors, such as genetics, hormones, age, smoking, inflammation, and diet, among others.[2,5,6]

Rapid advances in molecular biology techniques have led to the introduction of genetic polymorphisms, which have brought enormous benefits to BPH diagnosis. Many studies have focused on the relationship between vitamin D receptor (VDR) and the risk of BPH.[7,8] This gene has been shown to have essential functions in many diseases; such as cancer, cardiovascular disease, and tuberculosis.[9] First, Vit D is synthesized in the skin and mediates many actions in many tissues in the body.[10] It is metabolized to 1,25-dihydroxyvitamin D, which can regulate calcium and phosphate metabolism.

Then some gene expressions are regulated after 1,25-dihydroxyvitamin D combining with VDR.[11] Previous studies also found that low levels of vitamin D could be a risk of BPH.[8] The VDR gene is a member of the steroid hormone receptor superfamily and is found on chromosome 12, which has the 4 most common polymorphic loci: Fok-1, Bsm-1, Taq-1, and Apa-1.[12] It activates the vitamin D and forms a heterodimer complex that binds to the vitamin D response element.

This product leads to the transcriptional down-regulation of many genes and is thus involved in the development and progression of disease.[8,13,14]

Although genome-wide correlation studies have estimated the correlations between VDR polymorphisms and BPH in multiple populations, many findings remain conflicting.[7,15] El-Ezzi et al[16] and Zhang et al[17] presented similar results, suggesting that VDR polymorphisms may play a key role in predicting BPH in Lebanese and Chinese men. However, Bousemaa et al[15] came at the opposite conclusion. Zeng et al,[9] who conducted a meta-analysis on the association of VDR polymorphisms with the risk of BPH 8 years ago, did not reach definitive conclusions and stated that there were significant limitations.

This required an updated and comprehensive pooled analysis of these studies. Therefore, a meta-analysis of 10 relative papers on VDR polymorphisms associated with BPH was conducted with the aim of identifying more accurate and reliable results (Fig. 1).[7,8,13,15Not reported21]

Figure 1.

Flowchart of study selection based on the inclusion and exclusion criteria.

Figure image at the original source: open the original paper. This file is not included in this text import.
Source: 1. Introduction Source: 1. Introduction Source: 1. Introduction Source: 1. Introduction

Study methods

What methods does the paper describe?

2.1. Systematic retrieval strategy

We performed a comprehensive search for eligible studies on public databases of Embase (https://www.embase.com/), Web of science (https://www.webofscience.com/wos/woscc/basic-search), PubMed (https://pubmed.ncbi.nlm.nih.gov/), and China National Knowledge Internet (https://www.cnki.net/) from their initial dates to December 2022. The search terms in PubMed were “vitamin D receptor gene or VDR or 1-25 dihydroxycholecalciferol receptor gene,” “gene polymorphisms” and “BPH or benign prostatic hyperplasia.” According to the features of each electronic database, we also manually searched for all possible articles.

2.2. Inclusion criteria

The trials chosen must meet the following standards: case-control or cohort study; estimating the relationship between VDR polymorphisms and the BPH risk; offering genotype or allele frequency of VDR polymorphisms that can be assessed odds ratio (OR) and confidence interval (95% CI); literature was written in English and Chinese; the total score must be more than 5 points by using the Newcastle Ottawa Scale.

2.3. Data extraction

One author collected sufficient data from eligible researches, the details included the author’s name, publication county, year, race, study design, genotyping methods, source of controls, the number of attendees, Hardy: Weinberg equilibrium in cases and controls, the distributions of genotypes and alleles (Table 1).

Table 1

Characteristics of included studies.

StudyCountryEthnicityYearStudy designGenotype methodSource of controlCase-controlHWENOS
Chaimuangraj et al[7]ThailandAsian2006Case-controlPCRHB44/30Y6
Manchanda et al[8]IndiaCaucasian2010Case-controlPCR-RFLPHB160/160N6
Huang et al[13]ChinaAsian2006Case-controlPCR-RFLPHB189/502Y5
Bousemaa et al[15]NetherlandCaucasian2000Case-controlPCR-RFLPHB93/56Y6
Hamasaki et al[22]JapanAsian2002Case-controlPCRHB83/90Y6
El-Ezzi et al[16]LebanonCaucasian2014Case-controlPCR-RFLPHB68/79Y6
Zhang et al[17]ChinaAsian2017Case-controlPCR-RFLPHB452/501Y6
Ruan et al[18]ChinaAsian2015CohortPCR-RFLPHB200/200Y5
Habuchi et al[20]JapanAsia2000Case-controlPCR-RFLPPB209/128Y6
Nunes et al[21]AmericaCaucasian2016Case-controlPCR-RFLPBP41/169Y6

HB = hospital-based, HWE = Hardy: Weinberg equilibrium, N = non-HWE, NOS = Newcastle: Ottawa Scale, Y = HWE.

2.4. Statistical analysis

The P values of HWE in each study were recomputed by using the Chi-square test in SPSS software version 13.0 (SPSS Inc., Chicago, IL). The pooled OR and its 95% CI in 5 genetic models were calculated to evaluate the relationship between VDR gene polymorphisms and BPH risk. Z test identified the statistical significance of OR. homozygote model (WW vs ww), heterozygous model (Ww vs ww), dominant model (WW vs Ww/ww), over-dominant model (Ww vs WW/ww), recessive model (WW/Ww vs ww), and allele genetic model (W vs w allele) were conducted to estimate in our analysis.

In addition, we used Cochran Chi-square-based Q statistic and the inconsistency index (I2) to evaluate heterogeneity, the random-effects model was chosen appropriately because of P < 5% or I2 > 50%. Otherwise, a fixed-effects model was selected. Subgroup analysis based on the characteristics of ethnicities as well as sensitivity analysis were implemented in each outcome. Furthermore, we used Begg and Egger test to quantitatively estimate publication bias, P < 0.05 were considered publication bias. All data analysis were undertaken by using Stata version 12 (StataCorp LP, College Station, TX).

Source: 2. Method Source: 2. Method Source: 2. Method Source: 2. Method

Associations between VDR gene polymorphisms and the BPH risk

Results: Associations between VDR gene polymorphisms and the BPH risk

A combined analysis with 5 studies for the Apa-1 variant is shown in Table 2. In detail, no heterogeneity for Apa-1 except allelic model (I2 = 62.6%) and null significant association between Apa-1 variant and the risk of BPH were observed. Fixed effect model was used for subgroup analysis stratified by ethnicity, in which we found significant differences in allele genetic model in Caucasian population (W vs w allele: OR = 1.561, 95% CI = 1.096 to 2.223, P = .013).

Table 2

Results of the association between Apa-1 polymorphism and BPH risk in different ethnicities.

ComparisonStudiesOverall effectHeterogeneityPublic bias
OR (95% CI)Z-scoreP valueI2 (%)P valueBegg testEgger test
Whole
 WW vs ww51.078 (0.731 to 1.591)0.38.7040.6320.8060.998
 WW vs Ww50.962 (0.753 to 1.229)0.31.75630.7.2170.8060.172
 WW vs Ww/ww50.953 (0.755 to 1.202)0.41.68434.7.190.8060.246
 ww vs WW/Ww51.003 (0.753 to 1.335)0.02.9860.7490.4620.093
 Ww vs WW/ww51.039 (0.842 to 1.282)0.36.72118.3.2980.0860.038
 W vs w51.123 (0.830 to 1.519)0.75.45462.6.030.8060.246
Caucasian
 WW vs ww21.294 (0.630 to 2.658)0.7.4830.714
 WW vs Ww21.669 (0.908 to 3.068)1.65.0990.483
 WW vs Ww/ww21.566 (0.885 to 2.770)1.54.1240.493
 ww vs WW/Ww21.041 (0.608 to 1.782)0.15.8840.901
 Ww vs WW/ww20.718 (0.448 to 1.153)1.37.170.389
 W vs w21.561 (1.096 to 2.223)2.47.0130.38
Asian
 WW vs ww30.999 (0.629 to 1.586)0.9973.7.35410.466
 WW vs Ww30.864 (0.661 to 1.130)1.07.2860.47710.466
 WW vs Ww/ww30.865 (0.671 to 1.115)1.12.2614.5.35110.626
 ww vs WW/Ww30.988 (0.704 to 1.386)0.07.9430.3890.2960.117
 Ww vs WW/ww31.140 (0.900 to 1.442)1.09.2770.5330.2960.035
 W vs w30.942 (0.712 to 1.247)0.42.67743.1.17210.999

Homozygote model, WW vs ww; heterozygous model, WW vs Ww; dominant model, WW vs Ww/ww; recessive model, ww vs WW/Ww; over-dominant model, Ww vs WW/ww; allele genetic model, W vs W.

CI = confidence interval, OR = odds ratio.

Table 3 shows the fundamental relation between Bsm-I polymorphism and BPH. Fixed effect model was chosen for data analysis when I2 < 50%. Pooled results were not associated with BPH significantly under all comparison models, but contrary to recessive model (WW/Ww vs ww: OR = 0.307, 95% CI = 0.100 to 0.943, P = .039), over-dominant model (Ww vs WW/ww: OR = 2.194, 95% CI = 1.553 to 3.100, P = 0) in the subgroup of Caucasian population as well as recessive model (WW/Ww vs ww: OR = 2.019, 95% CI = 1.242 to 3.283, P = .039), over-dominant model (Ww vs WW/ww: OR = 0.437, 95% CI = 0.281 to 0.680, P = 0) in the subgroup of Asian population.

Table 3

Results of the association between Bsm-1 polymorphism and BPH risk in different ethnicities.

ComparisonStudiesOverall effectHeterogeneityPublic bias
OR (95% CI)Z-scoreP valueI2 (%)P valueBegg testEgger test
Whole
 WW vs ww51.774 (0.626 to 5.028)1.08.28177.4.0010.4620.77
 WW vs Ww50.788 (0.546 to 1.138)1.27.20445.5.1190.4620.302
 WW vs Ww/ww50.860 (0.605 to 1.222)0.84.411.6.340.4620.325
 ww vs WW/Ww50.599 (0.199 to 1.803)0.91.36291.300.4620.194
 Ww vs WW/ww51.371 (0.588 to 3.200)0.73.46588.800.8060.706
 W vs w51.068 (0.664 to 1.717)0.27.78781.40%00.8060.664
Caucasian
 WW vs ww32.717 (0.543 to 13.595)1.22.22486.8.0010.2960.569
 WW vs Ww30.678 (0.454 to 1.013)1.9.05844.5.16510.67
 WW vs Ww/ww30.769 (0.524 to 1.126)1.35.1770.2.36710.576
 ww vs WW/Ww30.307 (0.100 to 0.943)2.06.03984.3.00210.241
 Ww vs WW/ww32.194 (1.553 to 3.100)4.4507.3.3410.412
 W vs w31.372 (0.798 to 2.359)1.14.25279.9.00710.439
Asian
 WW vs ww20.881 (0.354 to 2.190)0.27.7840.994
 WW vs Ww21.841 (0.693 to 4.894)1.22.2210.54
 WW vs Ww/ww21.669 (0.647 to 4.303)1.06.2890.543
 ww vs WW/Ww22.019 (1.242 to 3.283)2.84.0059.9.292
 Ww vs WW/ww20.437 (0.281 to 0.680)3.6700.343
 W vs w20.618 (0.438 to 0.872)2.74.0060.425

Homozygote model, WW vs ww; heterozygous model, WW vs Ww; dominant model, WW vs Ww/ww; recessive model, ww vs WW/Ww; over-dominant model, Ww vs WW/ww; allele genetic model, W vs W.

CI = confidence interval, OR = odds ratio.

Outcomes of pooled analysis on the relevance between Taq-1 polymorphism and the BPH risk are displayed in Table 4. The result showed Taq-1 polymorphism could increase the risk of BPH in the multiple populations in the case of low heterogeneity, comparing of homozygote model (WW vs ww: OR = 2.194, 95% CI = 1.384 to 3.196, P = 0) (Fig. 2), heterozygous model (WW vs Ww: OR = 1.562, 95% CI = 1.207 to 2.021, P = .001), dominant model (WW vs Ww/ww: OR = 1.673, 95% CI = 1.312 to 2.133, P = 0), and allele genetic model (W vs w allele: OR = 1.443, 95% CI = 1.205 to 1.730, P = 0) (Fig. 3).

However, recessive model (WW/Ww vs ww: OR = 0.558, 95% CI = 0.392 to 0.795, P = .001) got a contrary result. Subsequently, Taq-1 variant confirmed similar effect in Caucasian population, such as homozygote model (WW vs ww: OR = 2.002, 95% CI = 1.276 to 3.141, P = .003), heterozygous model (WW vs Ww: OR = 1.674, 95% CI = 1.188 to 2.360, P = .003), dominant model (WW vs Ww/ww: OR = 1.800, 95% CI = 1.310 to 2.475, P = 0), allele genetic model (W vs w allele: OR = 1.419, 95% CI = 1.145 to 1.758, P = .001) and recessive model (WW/Ww vs ww: OR = 0.577, 95% CI = 0.398 to 0.837, P = .004).

In Asian population, the result showed significant association in dominant model (WW vs Ww/ww: OR = 1.507, 95% CI = 1.033 to 2.199, P = .033) as well as allele genetic model (W vs w allele: OR = 1.507, 95% CI = 1.075 to 2.112, P = .017). When analyzing in relevance between Taq-1 polymorphism and the volume of prostate, a result included 2 trials showed no association in recessive model (WW/Ww vs ww: OR = 1.284, 95% CI = 0.489 to 0.837, P = 3.376).

Table 4

Results of the association between Tap-1 polymorphism and BPH risk in different ethnicities.

ComparisonStudiesOverall effectHeterogeneityPublic bias
OR (95% CI)Z-scoreP valueI2(%)P valueBegg testEgger test
Whole
 WW vs ww72.103 (1.384 to 3.196)3.4800.9580.3680.413
 WW vs Ww71.562 (1.207 to 2.021)3.39.00127.8.21610.461
 WW vs Ww/ww71.673 (1.312 to 2.133)4.1508.6.3630.5480.374
 ww vs WW/Ww70.558 (0.392 to 0.795)3.24.0010.4510.7640.868
 Ww vs WW/ww70.760 (0.488 to 1.183)1.22.22468.2.0040.230.46
 W vs w71.443 (1.205 to 1.730)3.98021.1.2690.230.522
Caucasian
 WW vs ww42.002 (1.276 to 3.141)3.02.0030.8010.7340.482
 WW vs Ww41.674 (1.188 to 2.360)2.94.0030.46610.804
 WW vs Ww/ww41.800 (1.310 to 2.475)3.6200.92910.837
 ww vs WW/Ww40.577 (0.398 to 0.837)2.9.00441.8.1610.7340.065
 Ww vs WW/ww40.861 (0.448 to 1.653)0.45.65277.8.0040.7340.956
 W vs w41.419 (1.145 to 1.758)3.2.0010.4830.7340.2
Asian
 WW vs ww32.857 (0.908 to 8.987)1.8.0730.8970.2960.111
 WW vs Ww31.427 (0.965 to 2.109)1.78.07562.9.06810.423
 WW vs Ww/ww31.507 (1.033 to 2.199)2.13.03364.3.06110.436
 ww vs WW/Ww30.414 (0.133 to 1.294)1.52.1290.8530.2960.056
 Ww vs WW/ww30.626 (0.310 to 1.265)1.31.19259.9.08210.425
 W vs w31.507 (1.075 to 2.112)2.38.01760.6.07910.438

Homozygote model, WW vs ww; heterozygous model, WW vs Ww; dominant model, WW vs Ww/ww; recessive model, ww vs WW/Ww; over-dominant model, Ww vs WW/ww; allele genetic model, W vs W.

CI = confidence interval, OR = odds ratio.

Figure 2.

Forest plot of Tap-1 polymorphism and overall population with homozygote model (WW vs ww). CI = confidence interval, OR = odds ratio.

Figure image at the original source: open the original paper. This file is not included in this text import.
Figure 3.

Forest plot of Tap-1 polymorphism and overall population with the allelic model (W vs w). CI = confidence interval, OR = odds ratio.

Figure image at the original source: open the original paper. This file is not included in this text import.

A total of 910 cases and 1411 controls who are calculated Fok-1 variant and the susceptibility to BPH in Table 5. The results indicated that null significant association between Fok-1 polymorphism and the risk of BPH (Table 5) and clinical progression of BPH in Asian. The Fok-1 polymorphism was not associated with the volume of BPH by included 2 studies. When omitted 1 study that Fok-1 variant no matching to HWE, the pooled ORs were not significant change.

Table 5

Results of the association between Fok-1 polymorphism and BPH risk in different ethnicities.

ComparisonStudiesOverall effectHeterogeneityPublic bias
OR (95% CI)Z-scoreP valueI2 (%)P valueBegg testEgger test
Whole
 WW vs ww50.786 (0.546 to 1.131)1.3.19439.7.1560.4620.301
 WW vs Ww50.918 (0.643 to 1.309)0.48.63558.6.04710.884
 WW vs Ww/ww50.908 (0.449 to 1.219)0.54.59160.8.03710.868
 ww vs WW/Ww51.145 (0.625 to 2.097)0.44.66161.5.0340.4620.437
 Ww vs WW/ww51.142 (0.814 to 1.602)0.77.44465.4.02110.864
 W vs w51.057 (0.732 to 1.524)0.29.76882.2010.506
Caucasian
 WW vs ww30.670 (0.287 to 1.565)0.93.3550.8560.2960.002
 WW vs Ww30.956 (0.501 to 1.822)0.14.8953.4.170.2960.014
 WW vs Ww/ww31.068 (0.680 to 1.678)0.29.77522.9.2730.2960.138
 ww vs WW/Ww30.841 (0.367 to 1.928)0.41.68235.8.2110.2960.131
 Ww vs WW/ww31.158 (0.572 to 2.344)0.41.68476.4.01410.403
 W vs w31.324 (0.899 to 1.951)1.42.15653.3.1170.2960.303
Asian
 WW vs ww20.814 (0.544 to 1.219)1.31883.7.013
 WW vs Ww20.75 (0.544 to 1.219)0.75.45267.7.07
 WW vs Ww/ww20.824 (0.492 to 1.381)0.73.46379.2.028
 ww vs WW/Ww21.551 (0.518 to 4.646)0.78.43380.9.022
 Ww vs WW/ww21.173 (0.824 to 1.671)0.89.37659.9.114
 W vs w20.821 (0.501 to 1.347)0.78.43587.5.005

Homozygote model, WW vs ww; heterozygous model, WW vs Ww; dominant model, WW vs Ww/ww; recessive model, ww vs WW/Ww; over-dominant model, Ww vs WW/ww; allele genetic model, W vs W.

CI = confidence interval, OR = odds ratio.

Source: 3.1. Associations between VDR gene polymorphisms and the BPH risk Source: 3.1. Associations between VDR gene polymorphisms and the BPH risk Source: 3.1. Associations between VDR gene polymorphisms and the BPH risk Source: 3.1. Associations between VDR gene polymorphisms and the BPH risk Source: 3.1. Associations between VDR gene polymorphisms and the BPH risk Source: 3.1. Associations between VDR gene polymorphisms and the BPH risk Source: 3.1. Associations between VDR gene polymorphisms and the BPH risk Source: 3.1. Associations between VDR gene polymorphisms and the BPH risk Source: 3.1. Associations between VDR gene polymorphisms and the BPH risk Source: 3.1. Associations between VDR gene polymorphisms and the BPH risk

Results: Sensitive analysis and publication bias

The results of sensitivity analysis for VDR gene polymorphisms including Fok-1, Bsm-1, Taq-1, and Apa-1 were displayed respectively as forest maps in Supplementary 1a: d, Supplemental Digital Content, http://links.lww.com/MD/L802; http://links.lww.com/MD/L803; http://links.lww.com/MD/L804; http://links.lww.com/MD/L805. Furthermore, we implemented Begg test and Egger test to estimate the potential publication bias (Tables 2Not reported4). Some assessments of the funnel plots indicated no publication bias (Supplementary 2a: d, Supplemental Digital Content, http://links.lww.com/MD/L806; http://links.lww.com/MD/L807; http://links.lww.com/MD/L808; http://links.lww.com/MD/L809).

Table 2

Results of the association between Apa-1 polymorphism and BPH risk in different ethnicities.

ComparisonStudiesOverall effectHeterogeneityPublic bias
OR (95% CI)Z-scoreP valueI2 (%)P valueBegg testEgger test
Whole
 WW vs ww51.078 (0.731 to 1.591)0.38.7040.6320.8060.998
 WW vs Ww50.962 (0.753 to 1.229)0.31.75630.7.2170.8060.172
 WW vs Ww/ww50.953 (0.755 to 1.202)0.41.68434.7.190.8060.246
 ww vs WW/Ww51.003 (0.753 to 1.335)0.02.9860.7490.4620.093
 Ww vs WW/ww51.039 (0.842 to 1.282)0.36.72118.3.2980.0860.038
 W vs w51.123 (0.830 to 1.519)0.75.45462.6.030.8060.246
Caucasian
 WW vs ww21.294 (0.630 to 2.658)0.7.4830.714
 WW vs Ww21.669 (0.908 to 3.068)1.65.0990.483
 WW vs Ww/ww21.566 (0.885 to 2.770)1.54.1240.493
 ww vs WW/Ww21.041 (0.608 to 1.782)0.15.8840.901
 Ww vs WW/ww20.718 (0.448 to 1.153)1.37.170.389
 W vs w21.561 (1.096 to 2.223)2.47.0130.38
Asian
 WW vs ww30.999 (0.629 to 1.586)0.9973.7.35410.466
 WW vs Ww30.864 (0.661 to 1.130)1.07.2860.47710.466
 WW vs Ww/ww30.865 (0.671 to 1.115)1.12.2614.5.35110.626
 ww vs WW/Ww30.988 (0.704 to 1.386)0.07.9430.3890.2960.117
 Ww vs WW/ww31.140 (0.900 to 1.442)1.09.2770.5330.2960.035
 W vs w30.942 (0.712 to 1.247)0.42.67743.1.17210.999

Homozygote model, WW vs ww; heterozygous model, WW vs Ww; dominant model, WW vs Ww/ww; recessive model, ww vs WW/Ww; over-dominant model, Ww vs WW/ww; allele genetic model, W vs W.

CI = confidence interval, OR = odds ratio.

Table 4

Results of the association between Tap-1 polymorphism and BPH risk in different ethnicities.

ComparisonStudiesOverall effectHeterogeneityPublic bias
OR (95% CI)Z-scoreP valueI2(%)P valueBegg testEgger test
Whole
 WW vs ww72.103 (1.384 to 3.196)3.4800.9580.3680.413
 WW vs Ww71.562 (1.207 to 2.021)3.39.00127.8.21610.461
 WW vs Ww/ww71.673 (1.312 to 2.133)4.1508.6.3630.5480.374
 ww vs WW/Ww70.558 (0.392 to 0.795)3.24.0010.4510.7640.868
 Ww vs WW/ww70.760 (0.488 to 1.183)1.22.22468.2.0040.230.46
 W vs w71.443 (1.205 to 1.730)3.98021.1.2690.230.522
Caucasian
 WW vs ww42.002 (1.276 to 3.141)3.02.0030.8010.7340.482
 WW vs Ww41.674 (1.188 to 2.360)2.94.0030.46610.804
 WW vs Ww/ww41.800 (1.310 to 2.475)3.6200.92910.837
 ww vs WW/Ww40.577 (0.398 to 0.837)2.9.00441.8.1610.7340.065
 Ww vs WW/ww40.861 (0.448 to 1.653)0.45.65277.8.0040.7340.956
 W vs w41.419 (1.145 to 1.758)3.2.0010.4830.7340.2
Asian
 WW vs ww32.857 (0.908 to 8.987)1.8.0730.8970.2960.111
 WW vs Ww31.427 (0.965 to 2.109)1.78.07562.9.06810.423
 WW vs Ww/ww31.507 (1.033 to 2.199)2.13.03364.3.06110.436
 ww vs WW/Ww30.414 (0.133 to 1.294)1.52.1290.8530.2960.056
 Ww vs WW/ww30.626 (0.310 to 1.265)1.31.19259.9.08210.425
 W vs w31.507 (1.075 to 2.112)2.38.01760.6.07910.438

Homozygote model, WW vs ww; heterozygous model, WW vs Ww; dominant model, WW vs Ww/ww; recessive model, ww vs WW/Ww; over-dominant model, Ww vs WW/ww; allele genetic model, W vs W.

CI = confidence interval, OR = odds ratio.

Source: 3.2. Sensitive analysis and publication bias Source: 3.2. Sensitive analysis and publication bias Source: 3.2. Sensitive analysis and publication bias

Discussion

There is an increasing number of studies on the correlation between VDR polymorphisms and the risk of BPH, but the results remained inconclusive.[23,24] VDR may be may be a potential target gene for the treatment of BPH.[25,26] BPH was considered a hereditary disease, and the difference in VDR genotypes had a significant influence on the occurrence of BPH.[20] A meta-analysis with 7 literature was implemented in 2014, which seemed to be out of date because of new appeared analysis.[9] The shortage of this study was that they only carried out the overall analysis besides Taq-1 polymorphism.

We could not rule out the difference in ethnicity which might influence the results. Furthermore, the results came to change essentially when omitting some studies and most of the results had high heterogeneity. Finally, we performed the newest meta-analysis to assess the relationship between VDR gene polymorphisms and the BPH risk. The detailed subgroup analyses and sensitivity analyses of all the polymorphisms are conducted. The low heterogeneity results of this meta-analysis could provide more comprehensive results to determine the association between VDR gene polymorphisms and the BPH risk.

According to the outcomes of our meta-analysis, 3 of 4 VDR polymorphisms (Fok-1, Bsm-1, Apa-1) were not associated with the BPH risk in overall populations, which were similar to the results of prior meta-analysis.[9] Our meta-analysis omitted a cohort study by Mullan et al,[27] which included the Taq-1 and Bsm-1 polymorphisms because its Newcastle Ottawa Scale was <5 points. The data obtained in our study suggested that the Bsm-I variant recessive model in Caucasians and over-dominant model in Asians might be protective, while contrary to the over-dominant model in Caucasians and recessive model in Asians.

These results complemented the empty content of the previous meta-analysis on the Bsm-1 ethnicity subgroup due to a lack of data. The over-dominant model in Caucasians indicated a high heterogeneity concerning clinical heterogeneity, and the heterogeneity decreased when omitted El-Ezzi et al.[16] Thus, we were cautious about explaining the correlation between the over-dominant model and the risk of BPH in Caucasians. We observed that the allele genetic model of Apa-1 polymorphism increased the risk of BPH in Caucasians. significant heterogeneity between trials of Fok-1 polymorphism was detected, as the distributions of genetic models and the study design were quite different.

However, contrary to the low heterogeneity of the Fok-1 variant in the last meta-analysis, the experimental design and the number of included studies might play a key role in the high heterogeneity in our analysis. In addition, we found that almost studies accorded with HWE, which meant we could exclude the HWE might affect the stabilization and heterogeneity of results.

Furthermore, our result suggested that significant relationship between the Taq-1 variant and the risk of BPH exited in multi-populations. When analyzing the association between Taq-1 polymorphism and the BPH risk in multiple populations, the homozygote model, heterozygous model, dominant model, and allele genetic model might increase the risk of BPH. However, the recessive model got a declining result. We also observed that the homozygote model, heterozygous model, and dominant model in the Taq-1 variant in the Caucasian population got auxo-action for the BPH risk, while the recessive model was negative.

There was low heterogeneity in the above results which meant these studies were suitable to be pooled. When in the Asian population, the result showed a significant association between the dominant model and the allele genetic model.[28] The results indicated that ethnic differences could significantly alter the distribution of gene polymorphism models. However, it was worth noting that the heterogeneity of the dominant model and allele genetic model in Asians was >50%. After comparing data by software, it was considered that all the heterogeneity was derived from Habuchi et al.[20] But we couldn’t explain the heterogeneity at present.

So, the results come out in Asians to explain the correlation was conservative. In general, the obvious correlation between Taq-1 and BPH is different from that in the last meta-analysis, the different results might be caused by the quality and quantity of the included studies. When we considered the association between the prostate volume and Fok-1 and Taq-1 polymorphisms, null meaningful results were found. More studies should confirm this hypothesis in the future. There was no clinical application of the VDR polymorphisms to predict the risk of BPH.[29] According to current analysis results, Taq-1 polymorphisms might be a “star biomarker” to predict the appearance of BPH.

It should be mentioned that There were several limitations in the current meta-analysis. First of all, only 10 eligible trials were included in our analysis, which meant we need more studies to evaluate the relationship between VDR polymorphisms and the BPH risk that could increase the statistical power. As we all know, there were more than 14 VDR polymorphisms in the VDR gene.[30] So, we needed more studies to prove whether any association between other polymorphisms and the risk of BPH.

Furthermore, International Prostate Symptom Score, prostate volume, and other prostatic progression indexes should be considered in the future related to VDR polymorphisms. Second, publication and language bias could be present because we only searched for publications in Chinese and English. In addition, because of the lack of enough available information, only a sub-analysis based on ethnicity was performed. More detailed national and regional population studies could be carried out in the future. According to the mentions of Brustad et al[31] and Ruiz-Ballesteros et al,[30] we hypothesized that gene-gene, as well as gene-environment interactions, might interfere with our results.

Some similar studies could be conducted later on to verify gene-gene and gene-environment interactions. So, we could not ignore these potential parameters and we should be able to discuss their relationship further.

Source: 4. Discussion Source: 4. Discussion Source: 4. Discussion Source: 4. Discussion

Results

3.1. Associations between VDR gene polymorphisms and the BPH risk

A combined analysis with 5 studies for the Apa-1 variant is shown in Table 2. In detail, no heterogeneity for Apa-1 except allelic model (I2 = 62.6%) and null significant association between Apa-1 variant and the risk of BPH were observed. Fixed effect model was used for subgroup analysis stratified by ethnicity, in which we found significant differences in allele genetic model in Caucasian population (W vs w allele: OR = 1.561, 95% CI = 1.096 to 2.223, P = .013).

Table 2

Results of the association between Apa-1 polymorphism and BPH risk in different ethnicities.

ComparisonStudiesOverall effectHeterogeneityPublic bias
OR (95% CI)Z-scoreP valueI2 (%)P valueBegg testEgger test
Whole
 WW vs ww51.078 (0.731 to 1.591)0.38.7040.6320.8060.998
 WW vs Ww50.962 (0.753 to 1.229)0.31.75630.7.2170.8060.172
 WW vs Ww/ww50.953 (0.755 to 1.202)0.41.68434.7.190.8060.246
 ww vs WW/Ww51.003 (0.753 to 1.335)0.02.9860.7490.4620.093
 Ww vs WW/ww51.039 (0.842 to 1.282)0.36.72118.3.2980.0860.038
 W vs w51.123 (0.830 to 1.519)0.75.45462.6.030.8060.246
Caucasian
 WW vs ww21.294 (0.630 to 2.658)0.7.4830.714
 WW vs Ww21.669 (0.908 to 3.068)1.65.0990.483
 WW vs Ww/ww21.566 (0.885 to 2.770)1.54.1240.493
 ww vs WW/Ww21.041 (0.608 to 1.782)0.15.8840.901
 Ww vs WW/ww20.718 (0.448 to 1.153)1.37.170.389
 W vs w21.561 (1.096 to 2.223)2.47.0130.38
Asian
 WW vs ww30.999 (0.629 to 1.586)0.9973.7.35410.466
 WW vs Ww30.864 (0.661 to 1.130)1.07.2860.47710.466
 WW vs Ww/ww30.865 (0.671 to 1.115)1.12.2614.5.35110.626
 ww vs WW/Ww30.988 (0.704 to 1.386)0.07.9430.3890.2960.117
 Ww vs WW/ww31.140 (0.900 to 1.442)1.09.2770.5330.2960.035
 W vs w30.942 (0.712 to 1.247)0.42.67743.1.17210.999

Homozygote model, WW vs ww; heterozygous model, WW vs Ww; dominant model, WW vs Ww/ww; recessive model, ww vs WW/Ww; over-dominant model, Ww vs WW/ww; allele genetic model, W vs W.

CI = confidence interval, OR = odds ratio.

Table 3 shows the fundamental relation between Bsm-I polymorphism and BPH. Fixed effect model was chosen for data analysis when I2 < 50%. Pooled results were not associated with BPH significantly under all comparison models, but contrary to recessive model (WW/Ww vs ww: OR = 0.307, 95% CI = 0.100 to 0.943, P = .039), over-dominant model (Ww vs WW/ww: OR = 2.194, 95% CI = 1.553 to 3.100, P = 0) in the subgroup of Caucasian population as well as recessive model (WW/Ww vs ww: OR = 2.019, 95% CI = 1.242 to 3.283, P = .039), over-dominant model (Ww vs WW/ww: OR = 0.437, 95% CI = 0.281 to 0.680, P = 0) in the subgroup of Asian population.

Table 3

Results of the association between Bsm-1 polymorphism and BPH risk in different ethnicities.

ComparisonStudiesOverall effectHeterogeneityPublic bias
OR (95% CI)Z-scoreP valueI2 (%)P valueBegg testEgger test
Whole
 WW vs ww51.774 (0.626 to 5.028)1.08.28177.4.0010.4620.77
 WW vs Ww50.788 (0.546 to 1.138)1.27.20445.5.1190.4620.302
 WW vs Ww/ww50.860 (0.605 to 1.222)0.84.411.6.340.4620.325
 ww vs WW/Ww50.599 (0.199 to 1.803)0.91.36291.300.4620.194
 Ww vs WW/ww51.371 (0.588 to 3.200)0.73.46588.800.8060.706
 W vs w51.068 (0.664 to 1.717)0.27.78781.40%00.8060.664
Caucasian
 WW vs ww32.717 (0.543 to 13.595)1.22.22486.8.0010.2960.569
 WW vs Ww30.678 (0.454 to 1.013)1.9.05844.5.16510.67
 WW vs Ww/ww30.769 (0.524 to 1.126)1.35.1770.2.36710.576
 ww vs WW/Ww30.307 (0.100 to 0.943)2.06.03984.3.00210.241
 Ww vs WW/ww32.194 (1.553 to 3.100)4.4507.3.3410.412
 W vs w31.372 (0.798 to 2.359)1.14.25279.9.00710.439
Asian
 WW vs ww20.881 (0.354 to 2.190)0.27.7840.994
 WW vs Ww21.841 (0.693 to 4.894)1.22.2210.54
 WW vs Ww/ww21.669 (0.647 to 4.303)1.06.2890.543
 ww vs WW/Ww22.019 (1.242 to 3.283)2.84.0059.9.292
 Ww vs WW/ww20.437 (0.281 to 0.680)3.6700.343
 W vs w20.618 (0.438 to 0.872)2.74.0060.425

Homozygote model, WW vs ww; heterozygous model, WW vs Ww; dominant model, WW vs Ww/ww; recessive model, ww vs WW/Ww; over-dominant model, Ww vs WW/ww; allele genetic model, W vs W.

CI = confidence interval, OR = odds ratio.

Outcomes of pooled analysis on the relevance between Taq-1 polymorphism and the BPH risk are displayed in Table 4. The result showed Taq-1 polymorphism could increase the risk of BPH in the multiple populations in the case of low heterogeneity, comparing of homozygote model (WW vs ww: OR = 2.194, 95% CI = 1.384 to 3.196, P = 0) (Fig. 2), heterozygous model (WW vs Ww: OR = 1.562, 95% CI = 1.207 to 2.021, P = .001), dominant model (WW vs Ww/ww: OR = 1.673, 95% CI = 1.312 to 2.133, P = 0), and allele genetic model (W vs w allele: OR = 1.443, 95% CI = 1.205 to 1.730, P = 0) (Fig. 3).

However, recessive model (WW/Ww vs ww: OR = 0.558, 95% CI = 0.392 to 0.795, P = .001) got a contrary result. Subsequently, Taq-1 variant confirmed similar effect in Caucasian population, such as homozygote model (WW vs ww: OR = 2.002, 95% CI = 1.276 to 3.141, P = .003), heterozygous model (WW vs Ww: OR = 1.674, 95% CI = 1.188 to 2.360, P = .003), dominant model (WW vs Ww/ww: OR = 1.800, 95% CI = 1.310 to 2.475, P = 0), allele genetic model (W vs w allele: OR = 1.419, 95% CI = 1.145 to 1.758, P = .001) and recessive model (WW/Ww vs ww: OR = 0.577, 95% CI = 0.398 to 0.837, P = .004).

In Asian population, the result showed significant association in dominant model (WW vs Ww/ww: OR = 1.507, 95% CI = 1.033 to 2.199, P = .033) as well as allele genetic model (W vs w allele: OR = 1.507, 95% CI = 1.075 to 2.112, P = .017). When analyzing in relevance between Taq-1 polymorphism and the volume of prostate, a result included 2 trials showed no association in recessive model (WW/Ww vs ww: OR = 1.284, 95% CI = 0.489 to 0.837, P = 3.376).

Table 4

Results of the association between Tap-1 polymorphism and BPH risk in different ethnicities.

ComparisonStudiesOverall effectHeterogeneityPublic bias
OR (95% CI)Z-scoreP valueI2(%)P valueBegg testEgger test
Whole
 WW vs ww72.103 (1.384 to 3.196)3.4800.9580.3680.413
 WW vs Ww71.562 (1.207 to 2.021)3.39.00127.8.21610.461
 WW vs Ww/ww71.673 (1.312 to 2.133)4.1508.6.3630.5480.374
 ww vs WW/Ww70.558 (0.392 to 0.795)3.24.0010.4510.7640.868
 Ww vs WW/ww70.760 (0.488 to 1.183)1.22.22468.2.0040.230.46
 W vs w71.443 (1.205 to 1.730)3.98021.1.2690.230.522
Caucasian
 WW vs ww42.002 (1.276 to 3.141)3.02.0030.8010.7340.482
 WW vs Ww41.674 (1.188 to 2.360)2.94.0030.46610.804
 WW vs Ww/ww41.800 (1.310 to 2.475)3.6200.92910.837
 ww vs WW/Ww40.577 (0.398 to 0.837)2.9.00441.8.1610.7340.065
 Ww vs WW/ww40.861 (0.448 to 1.653)0.45.65277.8.0040.7340.956
 W vs w41.419 (1.145 to 1.758)3.2.0010.4830.7340.2
Asian
 WW vs ww32.857 (0.908 to 8.987)1.8.0730.8970.2960.111
 WW vs Ww31.427 (0.965 to 2.109)1.78.07562.9.06810.423
 WW vs Ww/ww31.507 (1.033 to 2.199)2.13.03364.3.06110.436
 ww vs WW/Ww30.414 (0.133 to 1.294)1.52.1290.8530.2960.056
 Ww vs WW/ww30.626 (0.310 to 1.265)1.31.19259.9.08210.425
 W vs w31.507 (1.075 to 2.112)2.38.01760.6.07910.438

Homozygote model, WW vs ww; heterozygous model, WW vs Ww; dominant model, WW vs Ww/ww; recessive model, ww vs WW/Ww; over-dominant model, Ww vs WW/ww; allele genetic model, W vs W.

CI = confidence interval, OR = odds ratio.

Figure 2.

Forest plot of Tap-1 polymorphism and overall population with homozygote model (WW vs ww). CI = confidence interval, OR = odds ratio.

Figure image at the original source: open the original paper. This file is not included in this text import.
Figure 3.

Forest plot of Tap-1 polymorphism and overall population with the allelic model (W vs w). CI = confidence interval, OR = odds ratio.

Figure image at the original source: open the original paper. This file is not included in this text import.

A total of 910 cases and 1411 controls who are calculated Fok-1 variant and the susceptibility to BPH in Table 5. The results indicated that null significant association between Fok-1 polymorphism and the risk of BPH (Table 5) and clinical progression of BPH in Asian. The Fok-1 polymorphism was not associated with the volume of BPH by included 2 studies. When omitted 1 study that Fok-1 variant no matching to HWE, the pooled ORs were not significant change.

Table 5

Results of the association between Fok-1 polymorphism and BPH risk in different ethnicities.

ComparisonStudiesOverall effectHeterogeneityPublic bias
OR (95% CI)Z-scoreP valueI2 (%)P valueBegg testEgger test
Whole
 WW vs ww50.786 (0.546 to 1.131)1.3.19439.7.1560.4620.301
 WW vs Ww50.918 (0.643 to 1.309)0.48.63558.6.04710.884
 WW vs Ww/ww50.908 (0.449 to 1.219)0.54.59160.8.03710.868
 ww vs WW/Ww51.145 (0.625 to 2.097)0.44.66161.5.0340.4620.437
 Ww vs WW/ww51.142 (0.814 to 1.602)0.77.44465.4.02110.864
 W vs w51.057 (0.732 to 1.524)0.29.76882.2010.506
Caucasian
 WW vs ww30.670 (0.287 to 1.565)0.93.3550.8560.2960.002
 WW vs Ww30.956 (0.501 to 1.822)0.14.8953.4.170.2960.014
 WW vs Ww/ww31.068 (0.680 to 1.678)0.29.77522.9.2730.2960.138
 ww vs WW/Ww30.841 (0.367 to 1.928)0.41.68235.8.2110.2960.131
 Ww vs WW/ww31.158 (0.572 to 2.344)0.41.68476.4.01410.403
 W vs w31.324 (0.899 to 1.951)1.42.15653.3.1170.2960.303
Asian
 WW vs ww20.814 (0.544 to 1.219)1.31883.7.013
 WW vs Ww20.75 (0.544 to 1.219)0.75.45267.7.07
 WW vs Ww/ww20.824 (0.492 to 1.381)0.73.46379.2.028
 ww vs WW/Ww21.551 (0.518 to 4.646)0.78.43380.9.022
 Ww vs WW/ww21.173 (0.824 to 1.671)0.89.37659.9.114
 W vs w20.821 (0.501 to 1.347)0.78.43587.5.005

Homozygote model, WW vs ww; heterozygous model, WW vs Ww; dominant model, WW vs Ww/ww; recessive model, ww vs WW/Ww; over-dominant model, Ww vs WW/ww; allele genetic model, W vs W.

CI = confidence interval, OR = odds ratio.

3.2. Sensitive analysis and publication bias

The results of sensitivity analysis for VDR gene polymorphisms including Fok-1, Bsm-1, Taq-1, and Apa-1 were displayed respectively as forest maps in Supplementary 1a: d, Supplemental Digital Content, http://links.lww.com/MD/L802; http://links.lww.com/MD/L803; http://links.lww.com/MD/L804; http://links.lww.com/MD/L805. Furthermore, we implemented Begg test and Egger test to estimate the potential publication bias (Tables 2Not reported4). Some assessments of the funnel plots indicated no publication bias (Supplementary 2a: d, Supplemental Digital Content, http://links.lww.com/MD/L806; http://links.lww.com/MD/L807; http://links.lww.com/MD/L808; http://links.lww.com/MD/L809).

Source: 3. Results Source: 3. Results

Conclusion

In conclusion, this meta-analysis might be the most updated one to assess the association between VDR polymorphisms and the BPH risk. With the limited number of included publications, our analysis evaluated the association of VDR polymorphisms with the risk of BPH, but not the progression of BPH. Thus, larger sample size studies should be carried out.

Source: 5. Conclusion
Authors’ abstract

Background:

Benign prostatic hyperplasia (BPH) is one of the global public health challenges due to the complexity of its mechanisms of occurrence. Many studies have suggested that vitamin D receptor gene polymorphisms are associated with BPH susceptibility. Still, their conflicting findings need to be analyzed in aggregate to gain a better understanding.

Methods:

We identified 10 trials involving 1539 BPH cases and 1915 controls through a systematic search of Embase using, data obtained from the Web of Science, PubMed, and China Knowledge Network databases as of December 31, 2021. A meta-analysis was performed to investigate the association between 4 constant polymorphisms of this associated vitamin D receptor gene (Fok-1, Bsm-1, Taq-1, and Apa-1) and BPH risk.

Results:

In the overall population analysis, a significant positive association with BPH risk was found only in the Taq-1 variant (P < .001). Of these, the pure-hybrid model (95% confidence interval [CI] = 1.384 to 3.196), the heterozygous model (95% CI = 1.207 to 2.021), the dominant model (95% CI = 1.312 to 2.133) and the allelic inheritance model (95% CI = 1.205 to 1.730) showed low heterogeneity. In subtype analyses, Bsm-1 variants showed a significant association with BPH risk for both the recessive (95% CI = 0.100 to 0.943, P = .039) and over-dominant (95% CI = 1.553 to 3.100, P = 0) models in the Caucasian population, and for the recessive (95% CI = 1.242 to 3.283, P = .039) and over-dominant (95% CI = 0.281 to 0.680, P = 0) models in the Asian population.

In addition, a high degree of heterogeneity was found in the subgroup analysis of the association between Fok-1 variants and BPH risk.

Conclusion:

Overall, there is an association between vitamin D receptor polymorphisms and BPH risk. Identification of BPH susceptibility by vitamin D receptor gene polymorphisms has potential.

Read the full paper

1. Introduction

Benign prostatic hyperplasia (BPH), a common benign neoplastic disease in aging male, has highly complex mechanisms and has become a significant worldwide public health issue.[1] Although many studies have been conducted in the past decades, the etiology of BPH cannot be completely explained. Moreover, as the population grows and ages, BPH brings with it a greater burden of health care and financial expense.[2] Lower urinary tract symptoms due to clinical BPH include nocturia, urgency, and frequency, which can obstruct bladder outlet, resulting in declining quality of life.[3,4] Some experiments suggested that the risk of BPH might be associated with many factors, such as genetics, hormones, age, smoking, inflammation, and diet, among others.[2,5,6]

Rapid advances in molecular biology techniques have led to the introduction of genetic polymorphisms, which have brought enormous benefits to BPH diagnosis. Many studies have focused on the relationship between vitamin D receptor (VDR) and the risk of BPH.[7,8] This gene has been shown to have essential functions in many diseases; such as cancer, cardiovascular disease, and tuberculosis.[9] First, Vit D is synthesized in the skin and mediates many actions in many tissues in the body.[10] It is metabolized to 1,25-dihydroxyvitamin D, which can regulate calcium and phosphate metabolism.

Then some gene expressions are regulated after 1,25-dihydroxyvitamin D combining with VDR.[11] Previous studies also found that low levels of vitamin D could be a risk of BPH.[8] The VDR gene is a member of the steroid hormone receptor superfamily and is found on chromosome 12, which has the 4 most common polymorphic loci: Fok-1, Bsm-1, Taq-1, and Apa-1.[12] It activates the vitamin D and forms a heterodimer complex that binds to the vitamin D response element.

This product leads to the transcriptional down-regulation of many genes and is thus involved in the development and progression of disease.[8,13,14]

Although genome-wide correlation studies have estimated the correlations between VDR polymorphisms and BPH in multiple populations, many findings remain conflicting.[7,15] El-Ezzi et al[16] and Zhang et al[17] presented similar results, suggesting that VDR polymorphisms may play a key role in predicting BPH in Lebanese and Chinese men. However, Bousemaa et al[15] came at the opposite conclusion. Zeng et al,[9] who conducted a meta-analysis on the association of VDR polymorphisms with the risk of BPH 8 years ago, did not reach definitive conclusions and stated that there were significant limitations.

This required an updated and comprehensive pooled analysis of these studies. Therefore, a meta-analysis of 10 relative papers on VDR polymorphisms associated with BPH was conducted with the aim of identifying more accurate and reliable results (Fig. 1).[7,8,13,15Not reported21]

Figure 1.

Flowchart of study selection based on the inclusion and exclusion criteria.

Figure image at the original source: open the original paper. This file is not included in this text import.

2. Method

2.1. Systematic retrieval strategy

We performed a comprehensive search for eligible studies on public databases of Embase (https://www.embase.com/), Web of science (https://www.webofscience.com/wos/woscc/basic-search), PubMed (https://pubmed.ncbi.nlm.nih.gov/), and China National Knowledge Internet (https://www.cnki.net/) from their initial dates to December 2022. The search terms in PubMed were “vitamin D receptor gene or VDR or 1-25 dihydroxycholecalciferol receptor gene,” “gene polymorphisms” and “BPH or benign prostatic hyperplasia.” According to the features of each electronic database, we also manually searched for all possible articles.

2.2. Inclusion criteria

The trials chosen must meet the following standards: case-control or cohort study; estimating the relationship between VDR polymorphisms and the BPH risk; offering genotype or allele frequency of VDR polymorphisms that can be assessed odds ratio (OR) and confidence interval (95% CI); literature was written in English and Chinese; the total score must be more than 5 points by using the Newcastle Ottawa Scale.

2.3. Data extraction

One author collected sufficient data from eligible researches, the details included the author’s name, publication county, year, race, study design, genotyping methods, source of controls, the number of attendees, Hardy: Weinberg equilibrium in cases and controls, the distributions of genotypes and alleles (Table 1).

Table 1

Characteristics of included studies.

StudyCountryEthnicityYearStudy designGenotype methodSource of controlCase-controlHWENOS
Chaimuangraj et al[7]ThailandAsian2006Case-controlPCRHB44/30Y6
Manchanda et al[8]IndiaCaucasian2010Case-controlPCR-RFLPHB160/160N6
Huang et al[13]ChinaAsian2006Case-controlPCR-RFLPHB189/502Y5
Bousemaa et al[15]NetherlandCaucasian2000Case-controlPCR-RFLPHB93/56Y6
Hamasaki et al[22]JapanAsian2002Case-controlPCRHB83/90Y6
El-Ezzi et al[16]LebanonCaucasian2014Case-controlPCR-RFLPHB68/79Y6
Zhang et al[17]ChinaAsian2017Case-controlPCR-RFLPHB452/501Y6
Ruan et al[18]ChinaAsian2015CohortPCR-RFLPHB200/200Y5
Habuchi et al[20]JapanAsia2000Case-controlPCR-RFLPPB209/128Y6
Nunes et al[21]AmericaCaucasian2016Case-controlPCR-RFLPBP41/169Y6

HB = hospital-based, HWE = Hardy: Weinberg equilibrium, N = non-HWE, NOS = Newcastle: Ottawa Scale, Y = HWE.

2.4. Statistical analysis

The P values of HWE in each study were recomputed by using the Chi-square test in SPSS software version 13.0 (SPSS Inc., Chicago, IL). The pooled OR and its 95% CI in 5 genetic models were calculated to evaluate the relationship between VDR gene polymorphisms and BPH risk. Z test identified the statistical significance of OR. homozygote model (WW vs ww), heterozygous model (Ww vs ww), dominant model (WW vs Ww/ww), over-dominant model (Ww vs WW/ww), recessive model (WW/Ww vs ww), and allele genetic model (W vs w allele) were conducted to estimate in our analysis.

In addition, we used Cochran Chi-square-based Q statistic and the inconsistency index (I2) to evaluate heterogeneity, the random-effects model was chosen appropriately because of P < 5% or I2 > 50%. Otherwise, a fixed-effects model was selected. Subgroup analysis based on the characteristics of ethnicities as well as sensitivity analysis were implemented in each outcome. Furthermore, we used Begg and Egger test to quantitatively estimate publication bias, P < 0.05 were considered publication bias. All data analysis were undertaken by using Stata version 12 (StataCorp LP, College Station, TX).

2.5. Data availability

All data generated or analyzed during this study are included in this published article.

3. Results

3.1. Associations between VDR gene polymorphisms and the BPH risk

A combined analysis with 5 studies for the Apa-1 variant is shown in Table 2. In detail, no heterogeneity for Apa-1 except allelic model (I2 = 62.6%) and null significant association between Apa-1 variant and the risk of BPH were observed. Fixed effect model was used for subgroup analysis stratified by ethnicity, in which we found significant differences in allele genetic model in Caucasian population (W vs w allele: OR = 1.561, 95% CI = 1.096 to 2.223, P = .013).

Table 2

Results of the association between Apa-1 polymorphism and BPH risk in different ethnicities.

ComparisonStudiesOverall effectHeterogeneityPublic bias
OR (95% CI)Z-scoreP valueI2 (%)P valueBegg testEgger test
Whole
 WW vs ww51.078 (0.731 to 1.591)0.38.7040.6320.8060.998
 WW vs Ww50.962 (0.753 to 1.229)0.31.75630.7.2170.8060.172
 WW vs Ww/ww50.953 (0.755 to 1.202)0.41.68434.7.190.8060.246
 ww vs WW/Ww51.003 (0.753 to 1.335)0.02.9860.7490.4620.093
 Ww vs WW/ww51.039 (0.842 to 1.282)0.36.72118.3.2980.0860.038
 W vs w51.123 (0.830 to 1.519)0.75.45462.6.030.8060.246
Caucasian
 WW vs ww21.294 (0.630 to 2.658)0.7.4830.714
 WW vs Ww21.669 (0.908 to 3.068)1.65.0990.483
 WW vs Ww/ww21.566 (0.885 to 2.770)1.54.1240.493
 ww vs WW/Ww21.041 (0.608 to 1.782)0.15.8840.901
 Ww vs WW/ww20.718 (0.448 to 1.153)1.37.170.389
 W vs w21.561 (1.096 to 2.223)2.47.0130.38
Asian
 WW vs ww30.999 (0.629 to 1.586)0.9973.7.35410.466
 WW vs Ww30.864 (0.661 to 1.130)1.07.2860.47710.466
 WW vs Ww/ww30.865 (0.671 to 1.115)1.12.2614.5.35110.626
 ww vs WW/Ww30.988 (0.704 to 1.386)0.07.9430.3890.2960.117
 Ww vs WW/ww31.140 (0.900 to 1.442)1.09.2770.5330.2960.035
 W vs w30.942 (0.712 to 1.247)0.42.67743.1.17210.999

Homozygote model, WW vs ww; heterozygous model, WW vs Ww; dominant model, WW vs Ww/ww; recessive model, ww vs WW/Ww; over-dominant model, Ww vs WW/ww; allele genetic model, W vs W.

CI = confidence interval, OR = odds ratio.

Table 3 shows the fundamental relation between Bsm-I polymorphism and BPH. Fixed effect model was chosen for data analysis when I2 < 50%. Pooled results were not associated with BPH significantly under all comparison models, but contrary to recessive model (WW/Ww vs ww: OR = 0.307, 95% CI = 0.100 to 0.943, P = .039), over-dominant model (Ww vs WW/ww: OR = 2.194, 95% CI = 1.553 to 3.100, P = 0) in the subgroup of Caucasian population as well as recessive model (WW/Ww vs ww: OR = 2.019, 95% CI = 1.242 to 3.283, P = .039), over-dominant model (Ww vs WW/ww: OR = 0.437, 95% CI = 0.281 to 0.680, P = 0) in the subgroup of Asian population.

Table 3

Results of the association between Bsm-1 polymorphism and BPH risk in different ethnicities.

ComparisonStudiesOverall effectHeterogeneityPublic bias
OR (95% CI)Z-scoreP valueI2 (%)P valueBegg testEgger test
Whole
 WW vs ww51.774 (0.626 to 5.028)1.08.28177.4.0010.4620.77
 WW vs Ww50.788 (0.546 to 1.138)1.27.20445.5.1190.4620.302
 WW vs Ww/ww50.860 (0.605 to 1.222)0.84.411.6.340.4620.325
 ww vs WW/Ww50.599 (0.199 to 1.803)0.91.36291.300.4620.194
 Ww vs WW/ww51.371 (0.588 to 3.200)0.73.46588.800.8060.706
 W vs w51.068 (0.664 to 1.717)0.27.78781.40%00.8060.664
Caucasian
 WW vs ww32.717 (0.543 to 13.595)1.22.22486.8.0010.2960.569
 WW vs Ww30.678 (0.454 to 1.013)1.9.05844.5.16510.67
 WW vs Ww/ww30.769 (0.524 to 1.126)1.35.1770.2.36710.576
 ww vs WW/Ww30.307 (0.100 to 0.943)2.06.03984.3.00210.241
 Ww vs WW/ww32.194 (1.553 to 3.100)4.4507.3.3410.412
 W vs w31.372 (0.798 to 2.359)1.14.25279.9.00710.439
Asian
 WW vs ww20.881 (0.354 to 2.190)0.27.7840.994
 WW vs Ww21.841 (0.693 to 4.894)1.22.2210.54
 WW vs Ww/ww21.669 (0.647 to 4.303)1.06.2890.543
 ww vs WW/Ww22.019 (1.242 to 3.283)2.84.0059.9.292
 Ww vs WW/ww20.437 (0.281 to 0.680)3.6700.343
 W vs w20.618 (0.438 to 0.872)2.74.0060.425

Homozygote model, WW vs ww; heterozygous model, WW vs Ww; dominant model, WW vs Ww/ww; recessive model, ww vs WW/Ww; over-dominant model, Ww vs WW/ww; allele genetic model, W vs W.

CI = confidence interval, OR = odds ratio.

Outcomes of pooled analysis on the relevance between Taq-1 polymorphism and the BPH risk are displayed in Table 4. The result showed Taq-1 polymorphism could increase the risk of BPH in the multiple populations in the case of low heterogeneity, comparing of homozygote model (WW vs ww: OR = 2.194, 95% CI = 1.384 to 3.196, P = 0) (Fig. 2), heterozygous model (WW vs Ww: OR = 1.562, 95% CI = 1.207 to 2.021, P = .001), dominant model (WW vs Ww/ww: OR = 1.673, 95% CI = 1.312 to 2.133, P = 0), and allele genetic model (W vs w allele: OR = 1.443, 95% CI = 1.205 to 1.730, P = 0) (Fig. 3).

However, recessive model (WW/Ww vs ww: OR = 0.558, 95% CI = 0.392 to 0.795, P = .001) got a contrary result. Subsequently, Taq-1 variant confirmed similar effect in Caucasian population, such as homozygote model (WW vs ww: OR = 2.002, 95% CI = 1.276 to 3.141, P = .003), heterozygous model (WW vs Ww: OR = 1.674, 95% CI = 1.188 to 2.360, P = .003), dominant model (WW vs Ww/ww: OR = 1.800, 95% CI = 1.310 to 2.475, P = 0), allele genetic model (W vs w allele: OR = 1.419, 95% CI = 1.145 to 1.758, P = .001) and recessive model (WW/Ww vs ww: OR = 0.577, 95% CI = 0.398 to 0.837, P = .004).

In Asian population, the result showed significant association in dominant model (WW vs Ww/ww: OR = 1.507, 95% CI = 1.033 to 2.199, P = .033) as well as allele genetic model (W vs w allele: OR = 1.507, 95% CI = 1.075 to 2.112, P = .017). When analyzing in relevance between Taq-1 polymorphism and the volume of prostate, a result included 2 trials showed no association in recessive model (WW/Ww vs ww: OR = 1.284, 95% CI = 0.489 to 0.837, P = 3.376).

Table 4

Results of the association between Tap-1 polymorphism and BPH risk in different ethnicities.

ComparisonStudiesOverall effectHeterogeneityPublic bias
OR (95% CI)Z-scoreP valueI2(%)P valueBegg testEgger test
Whole
 WW vs ww72.103 (1.384 to 3.196)3.4800.9580.3680.413
 WW vs Ww71.562 (1.207 to 2.021)3.39.00127.8.21610.461
 WW vs Ww/ww71.673 (1.312 to 2.133)4.1508.6.3630.5480.374
 ww vs WW/Ww70.558 (0.392 to 0.795)3.24.0010.4510.7640.868
 Ww vs WW/ww70.760 (0.488 to 1.183)1.22.22468.2.0040.230.46
 W vs w71.443 (1.205 to 1.730)3.98021.1.2690.230.522
Caucasian
 WW vs ww42.002 (1.276 to 3.141)3.02.0030.8010.7340.482
 WW vs Ww41.674 (1.188 to 2.360)2.94.0030.46610.804
 WW vs Ww/ww41.800 (1.310 to 2.475)3.6200.92910.837
 ww vs WW/Ww40.577 (0.398 to 0.837)2.9.00441.8.1610.7340.065
 Ww vs WW/ww40.861 (0.448 to 1.653)0.45.65277.8.0040.7340.956
 W vs w41.419 (1.145 to 1.758)3.2.0010.4830.7340.2
Asian
 WW vs ww32.857 (0.908 to 8.987)1.8.0730.8970.2960.111
 WW vs Ww31.427 (0.965 to 2.109)1.78.07562.9.06810.423
 WW vs Ww/ww31.507 (1.033 to 2.199)2.13.03364.3.06110.436
 ww vs WW/Ww30.414 (0.133 to 1.294)1.52.1290.8530.2960.056
 Ww vs WW/ww30.626 (0.310 to 1.265)1.31.19259.9.08210.425
 W vs w31.507 (1.075 to 2.112)2.38.01760.6.07910.438

Homozygote model, WW vs ww; heterozygous model, WW vs Ww; dominant model, WW vs Ww/ww; recessive model, ww vs WW/Ww; over-dominant model, Ww vs WW/ww; allele genetic model, W vs W.

CI = confidence interval, OR = odds ratio.

Figure 2.

Forest plot of Tap-1 polymorphism and overall population with homozygote model (WW vs ww). CI = confidence interval, OR = odds ratio.

Figure image at the original source: open the original paper. This file is not included in this text import.
Figure 3.

Forest plot of Tap-1 polymorphism and overall population with the allelic model (W vs w). CI = confidence interval, OR = odds ratio.

Figure image at the original source: open the original paper. This file is not included in this text import.

A total of 910 cases and 1411 controls who are calculated Fok-1 variant and the susceptibility to BPH in Table 5. The results indicated that null significant association between Fok-1 polymorphism and the risk of BPH (Table 5) and clinical progression of BPH in Asian. The Fok-1 polymorphism was not associated with the volume of BPH by included 2 studies. When omitted 1 study that Fok-1 variant no matching to HWE, the pooled ORs were not significant change.

Table 5

Results of the association between Fok-1 polymorphism and BPH risk in different ethnicities.

ComparisonStudiesOverall effectHeterogeneityPublic bias
OR (95% CI)Z-scoreP valueI2 (%)P valueBegg testEgger test
Whole
 WW vs ww50.786 (0.546 to 1.131)1.3.19439.7.1560.4620.301
 WW vs Ww50.918 (0.643 to 1.309)0.48.63558.6.04710.884
 WW vs Ww/ww50.908 (0.449 to 1.219)0.54.59160.8.03710.868
 ww vs WW/Ww51.145 (0.625 to 2.097)0.44.66161.5.0340.4620.437
 Ww vs WW/ww51.142 (0.814 to 1.602)0.77.44465.4.02110.864
 W vs w51.057 (0.732 to 1.524)0.29.76882.2010.506
Caucasian
 WW vs ww30.670 (0.287 to 1.565)0.93.3550.8560.2960.002
 WW vs Ww30.956 (0.501 to 1.822)0.14.8953.4.170.2960.014
 WW vs Ww/ww31.068 (0.680 to 1.678)0.29.77522.9.2730.2960.138
 ww vs WW/Ww30.841 (0.367 to 1.928)0.41.68235.8.2110.2960.131
 Ww vs WW/ww31.158 (0.572 to 2.344)0.41.68476.4.01410.403
 W vs w31.324 (0.899 to 1.951)1.42.15653.3.1170.2960.303
Asian
 WW vs ww20.814 (0.544 to 1.219)1.31883.7.013
 WW vs Ww20.75 (0.544 to 1.219)0.75.45267.7.07
 WW vs Ww/ww20.824 (0.492 to 1.381)0.73.46379.2.028
 ww vs WW/Ww21.551 (0.518 to 4.646)0.78.43380.9.022
 Ww vs WW/ww21.173 (0.824 to 1.671)0.89.37659.9.114
 W vs w20.821 (0.501 to 1.347)0.78.43587.5.005

Homozygote model, WW vs ww; heterozygous model, WW vs Ww; dominant model, WW vs Ww/ww; recessive model, ww vs WW/Ww; over-dominant model, Ww vs WW/ww; allele genetic model, W vs W.

CI = confidence interval, OR = odds ratio.

3.2. Sensitive analysis and publication bias

The results of sensitivity analysis for VDR gene polymorphisms including Fok-1, Bsm-1, Taq-1, and Apa-1 were displayed respectively as forest maps in Supplementary 1a: d, Supplemental Digital Content, http://links.lww.com/MD/L802; http://links.lww.com/MD/L803; http://links.lww.com/MD/L804; http://links.lww.com/MD/L805. Furthermore, we implemented Begg test and Egger test to estimate the potential publication bias (Tables 2Not reported4). Some assessments of the funnel plots indicated no publication bias (Supplementary 2a: d, Supplemental Digital Content, http://links.lww.com/MD/L806; http://links.lww.com/MD/L807; http://links.lww.com/MD/L808; http://links.lww.com/MD/L809).

4. Discussion

There is an increasing number of studies on the correlation between VDR polymorphisms and the risk of BPH, but the results remained inconclusive.[23,24] VDR may be may be a potential target gene for the treatment of BPH.[25,26] BPH was considered a hereditary disease, and the difference in VDR genotypes had a significant influence on the occurrence of BPH.[20] A meta-analysis with 7 literature was implemented in 2014, which seemed to be out of date because of new appeared analysis.[9] The shortage of this study was that they only carried out the overall analysis besides Taq-1 polymorphism.

We could not rule out the difference in ethnicity which might influence the results. Furthermore, the results came to change essentially when omitting some studies and most of the results had high heterogeneity. Finally, we performed the newest meta-analysis to assess the relationship between VDR gene polymorphisms and the BPH risk. The detailed subgroup analyses and sensitivity analyses of all the polymorphisms are conducted. The low heterogeneity results of this meta-analysis could provide more comprehensive results to determine the association between VDR gene polymorphisms and the BPH risk.

According to the outcomes of our meta-analysis, 3 of 4 VDR polymorphisms (Fok-1, Bsm-1, Apa-1) were not associated with the BPH risk in overall populations, which were similar to the results of prior meta-analysis.[9] Our meta-analysis omitted a cohort study by Mullan et al,[27] which included the Taq-1 and Bsm-1 polymorphisms because its Newcastle Ottawa Scale was <5 points. The data obtained in our study suggested that the Bsm-I variant recessive model in Caucasians and over-dominant model in Asians might be protective, while contrary to the over-dominant model in Caucasians and recessive model in Asians.

These results complemented the empty content of the previous meta-analysis on the Bsm-1 ethnicity subgroup due to a lack of data. The over-dominant model in Caucasians indicated a high heterogeneity concerning clinical heterogeneity, and the heterogeneity decreased when omitted El-Ezzi et al.[16] Thus, we were cautious about explaining the correlation between the over-dominant model and the risk of BPH in Caucasians. We observed that the allele genetic model of Apa-1 polymorphism increased the risk of BPH in Caucasians. significant heterogeneity between trials of Fok-1 polymorphism was detected, as the distributions of genetic models and the study design were quite different.

However, contrary to the low heterogeneity of the Fok-1 variant in the last meta-analysis, the experimental design and the number of included studies might play a key role in the high heterogeneity in our analysis. In addition, we found that almost studies accorded with HWE, which meant we could exclude the HWE might affect the stabilization and heterogeneity of results.

Furthermore, our result suggested that significant relationship between the Taq-1 variant and the risk of BPH exited in multi-populations. When analyzing the association between Taq-1 polymorphism and the BPH risk in multiple populations, the homozygote model, heterozygous model, dominant model, and allele genetic model might increase the risk of BPH. However, the recessive model got a declining result. We also observed that the homozygote model, heterozygous model, and dominant model in the Taq-1 variant in the Caucasian population got auxo-action for the BPH risk, while the recessive model was negative.

There was low heterogeneity in the above results which meant these studies were suitable to be pooled. When in the Asian population, the result showed a significant association between the dominant model and the allele genetic model.[28] The results indicated that ethnic differences could significantly alter the distribution of gene polymorphism models. However, it was worth noting that the heterogeneity of the dominant model and allele genetic model in Asians was >50%. After comparing data by software, it was considered that all the heterogeneity was derived from Habuchi et al.[20] But we couldn’t explain the heterogeneity at present.

So, the results come out in Asians to explain the correlation was conservative. In general, the obvious correlation between Taq-1 and BPH is different from that in the last meta-analysis, the different results might be caused by the quality and quantity of the included studies. When we considered the association between the prostate volume and Fok-1 and Taq-1 polymorphisms, null meaningful results were found. More studies should confirm this hypothesis in the future. There was no clinical application of the VDR polymorphisms to predict the risk of BPH.[29] According to current analysis results, Taq-1 polymorphisms might be a “star biomarker” to predict the appearance of BPH.

It should be mentioned that There were several limitations in the current meta-analysis. First of all, only 10 eligible trials were included in our analysis, which meant we need more studies to evaluate the relationship between VDR polymorphisms and the BPH risk that could increase the statistical power. As we all know, there were more than 14 VDR polymorphisms in the VDR gene.[30] So, we needed more studies to prove whether any association between other polymorphisms and the risk of BPH.

Furthermore, International Prostate Symptom Score, prostate volume, and other prostatic progression indexes should be considered in the future related to VDR polymorphisms. Second, publication and language bias could be present because we only searched for publications in Chinese and English. In addition, because of the lack of enough available information, only a sub-analysis based on ethnicity was performed. More detailed national and regional population studies could be carried out in the future. According to the mentions of Brustad et al[31] and Ruiz-Ballesteros et al,[30] we hypothesized that gene-gene, as well as gene-environment interactions, might interfere with our results.

Some similar studies could be conducted later on to verify gene-gene and gene-environment interactions. So, we could not ignore these potential parameters and we should be able to discuss their relationship further.

5. Conclusion

In conclusion, this meta-analysis might be the most updated one to assess the association between VDR polymorphisms and the BPH risk. With the limited number of included publications, our analysis evaluated the association of VDR polymorphisms with the risk of BPH, but not the progression of BPH. Thus, larger sample size studies should be carried out.

Author contributions

Conceptualization, data curation, formal analysis, funding acquisition, investigation, methodology, project administration, resources, writing: original draft, writing: review & editing: Li Ruan.

Supplementary Material

Supplement file at the original source: open the original paper. This file is not included in this text import.
Supplement file at the original source: open the original paper. This file is not included in this text import.
Supplement file at the original source: open the original paper. This file is not included in this text import.
Supplement file at the original source: open the original paper. This file is not included in this text import.
Supplement file at the original source: open the original paper. This file is not included in this text import.
Supplement file at the original source: open the original paper. This file is not included in this text import.
Supplement file at the original source: open the original paper. This file is not included in this text import.
Supplement file at the original source: open the original paper. This file is not included in this text import.

Abbreviations:

BPH

Benign prostatic hyperplasia

HWE

Hardy: Weinberg equilibrium

NOS

Newcastle Ottawa Scale

VDR

vitamin D receptor

Supplemental Digital Content is available for this article.

This study was supported by Guangzhou Medical and Health Science and Technology Project (item number: 20161A011021) and Guangzhou Health Science and Technology Project (item number: 20181A010018).

The authors have no conflicts of interest to disclose.

Ethical review and approval were not required for the study on human participants in accordance with the local legislation and institutional requirements.

Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

All data generated or analyzed during this study are included in this published article [and its supplementary information files].

How to cite this article: Ruan L. Association between vitamin D receptor gene polymorphisms and genetic susceptibility to benign prostatic hyperplasia: A systematic review and meta-analysis. Medicine 2024;103:9(e37361).

References

[1] Lerner LB McVary KT Barry MJ . Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE PART I: initial work-up and medical management. J Urol . 2021 ;206 :806Not reported17 . 34384237 10.1097/JU.0000000000002183
[2] Devlin CM Simms MS Maitland NJ . Benign prostatic hyperplasia: what do we know? BJU Int . 2021 ;127 :389Not reported99 . 32893964 10.1111/bju.15229
[3] Qian XQ Xu D Liu HL . Genetic variants in 5p13.2 and 7q21.1 are associated with treatment for benign prostatic hyperplasia with the alpha-adrenergic receptor antagonist. Aging Male . 2017 ;20 :250Not reported6 . 28787260 10.1080/13685538.2017.1358261
[4] Na R Helfand BT Chen HT . A genetic variant near GATA3 implicated in inherited susceptibility and etiology of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). Prostate . 2017 ;77 :1213Not reported20 . 28656603 10.1002/pros.23380 PMC5565164
[5] AlChalabi R Wali MH Al-Ugaili DN . Association between single nucleotide polymorphisms of vitamin D receptor gene and diabetes with progression of benign prostatic hyperplasia. Ann Trop Med Public Health . 2020 ;23 :444Not reported54 .
[6] Kayode OT Owolabi AV Kayode AAA . Biochemical and histomorphological changes in testosterone propionate-induced benign prostatic hyperplasia in male Wistar rats treated with ketogenic diet. Biomed Pharmacother . 2020 ;132 :110863 . 33113424 10.1016/j.biopha.2020.110863
[7] Chaimuangraj S Thammachoti R Ongphiphadhanakul B . Lack of association of VDR polymorphisms with Thai prostate cancer as compared with benign prostate hyperplasia and controls. Asian Pac J Cancer Prev . 2006 ;7 :136Not reported9 . 16629532
[8] Manchanda PK Konwar R Nayak VL . Association of genetic variants of the vitamin D receptor (VDR) gene (Fok-1, Taq-1 & Bsm-1) with susceptibility of benign prostatic hyperplasia in a North Indian population. Asian Pac J Cancer Prev . 2010 ;11 :1005Not reported8 . 21133615
[9] Zeng XT Yao QS Weng H . Meta-analysis of vitamin D receptor gene polymorphisms and benign prostatic hyperplasia risk. Mol Biol Rep . 2014 ;41 :6713Not reported7 . 24990700 10.1007/s11033-014-3554-2
[10] Lu C Zhou W He X . Vitamin D status and vitamin D receptor genotypes in celiac disease: a meta-analysis. Crit Rev Food Sci Nutr . 2021 ;61 :2098Not reported106 . 32508121 10.1080/10408398.2020.1772716
[11] Barry EL Peacock JL Rees JR . Vitamin D receptor genotype, vitamin D3 supplementation, and risk of colorectal adenomas: a randomized clinical trial. JAMA Oncol . 2017 ;3 :628Not reported35 . 27978548 10.1001/jamaoncol.2016.5917 PMC5580351
[12] Latacz M Rozmus D Fiedorowicz E . Vitamin D receptor (VDR) gene polymorphism in patients diagnosed with colorectal cancer. Nutrients . 2021 ;13 :200 . 33440610 10.3390/nu13010200 PMC7826796
[13] Huang SP Huang CY Wu WJ . Association of vitamin D receptor Fok-1 polymorphism with prostate cancer risk, clinicopathological features and recurrence of prostate specific antigen after radical prostatectomy. Int J Cancer . 2006 ;119 :1902Not reported7 . 16708371 10.1002/ijc.22053
[14] Zhou Q Wen S Liu M . Association between gene polymorphisms of vitamin D receptor and gestational diabetes mellitus: a systematic review and meta-analysis. Int J Environ Res Public Health . 2020 ;18 :205 . 33383970 10.3390/ijerph18010205 PMC7794905
[15] Bousemaa JT Bussemakers MJG Houwelingen KP . Polymorphisms in the vitamin D receptor gene and the androgen receptor gene and the risk of benign prostatic hyperplasia. Eur Urol . 2000 ;37 :234Not reported8 . 10705205 10.1159/000020124
[16] El-Ezzi AA Zaidan WR El-Saidi MA . Association of benign prostate hyperplasia with polymorphisms in VDR, CYP17, and SRD5A2 genes among Lebanese men. Asian Pac J Cancer Prev . 2014 ;15 :1255Not reported62 . 24606449 10.7314/apjcp.2014.15.3.1255
[17] Zhang LL Song Y He LL . Associations of SRD5A2/CYP17/CYP19/VDR gene polymorphisms with the development and clinical progression of benign prostatic hyperplasia: a case-control study in northern Chinese population. Int J Clin Exp Pathol . 2017 ;10 :8660Not reported76 . 31966724 PMC6965420
[18] Ruan L Zhu JG Pan C . Association between single nucleotide polymorphism of vitamin D receptor gene Fok-1 polymorphism and clinical progress of benign prostatic hyperplasia. ScientificWorldJournal . 2015 ;2015 :235895 . 25685834 10.1155/2015/235895 PMC4320849
[19] Schatzl G Gsur A Bernhofer G . Association of vitamin D receptor and 17 Hydroxylase Gene polymorphisms with benign prostatic hyperplasia and Benign prostatic enlargement. Urology . 2000 ;57 :567Not reported72 . 10.1016/s0090-4295(00)01004-9 11248649
[20] Habuchi T Suzuki T Sasaki R . Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population. Cancer Res . 2000 ;60 :305Not reported8 . 10667581
[21] Nunes SBR Oliveira FM Neves AF . Association of vitamin D receptor variants with clinical parameters in prostate cancer. Springerplus . 2016 ;5 :364 . 27066374 10.1186/s40064-016-2009-8 PMC4805678
[22] Hamasaki T Inatomi H Katoh T . Significance of vitamin D receptor gene polymorphism for risk and disease severity of prostate cancer and benign prostatic hyperplasia in Japanese. Urol Int . 2002 ;68 :226Not reported31 . 12053022 10.1159/000058440
[23] Lee Ch L Lee J Na YJ . Combined effect of polymorphisms in type III 5-α reductase and androgen receptor gene with the risk of benign prostatic hyperplasia in Korea. J Exerc Rehabil . 2016 ;12 :504Not reported8 . 27807533 10.12965/jer.1632802.401 PMC5091070
[24] Taheri M Pouresmaeili F Omrani MD . Association of ANRIL gene polymorphisms with prostate cancer and benign prostatic hyperplasia in an Iranian population. Biomark Med . 2017 ;11 :413Not reported22 . 28621612 10.2217/bmm-2016-0378
[25] Manchanda PK Kibler AJ Zhang M . Vitamin D receptor as a therapeutic target for benign prostatic hyperplasia. Indian J Urol . 2012 ;28 :377Not reported81 . 23450267 10.4103/0970-1591.105745 PMC3579114
[26] Lin L Li P Liu X . Systematic review and meta-analysis of candidate gene association studies of benign prostate hyperplasia. Syst Rev . 2022 ;11 :60 . 35382870 10.1186/s13643-022-01914-7 PMC8985373
[27] Mullan RJ Bergstralh EJ Farmer SA . Growth factor, cytokine, and vitamin D receptor polymorphisms and risk of benign prostatic hyperplasia in a community-based cohort of men. Urology . 2006 ;67 :300Not reported5 . 16461080 10.1016/j.urology.2005.08.061
[28] Kim SK Chung JH Park HC . Association between polymorphisms of estrogen receptor 2 and benign prostatic hyperplasia. Exp Ther Med . 2015 ;10 :1990Not reported4 . 26640585 10.3892/etm.2015.2755 PMC4665750
[29] Swami S Krishnan AV Feldman D . Vitamin D metabolism and action in the prostate: implications for health and disease. Mol Cell Endocrinol . 2011 ;347 :61Not reported9 . 21664249 10.1016/j.mce.2011.05.010 PMC3189327
[30] Ruiz-Ballesteros AI Meza-Meza MR Vizmanos-Lamotte B . Association of vitamin D metabolism gene polymorphisms with autoimmunity: evidence in population genetic studies. Int J Mol Sci . 2020 ;21 :9626 . 33348854 10.3390/ijms21249626 PMC7766382
[31] Brustad N Greve JH Mirzakhani H . High-dose vitamin D during pregnancy and pathway gene polymorphisms in prevention of offspring persistent wheeze. Pediatr Allergy Immunol . 2021 ;32 :679Not reported89 . 33453076 10.1111/pai.13453
Publication and source details

Original title: Association between vitamin D receptor gene polymorphisms and genetic susceptibility to benign prostatic hyperplasia: A systematic review and meta-analysis

Li Ruan

Medicine · 2024

* Correspondence: Li Ruan, Department of Urology, Guangzhou Red Cross Hospital (Guangzhou Red Cross Hospital of Jinan University) (e-mail: ruanli1978@126.com).Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.2024https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T05:03:17.728535+00:00

DOI: 10.1097/md.0000000000037361 · PMC10906597